Crown Bioscience spinoff Apollomics has closed a round led by Ping An Capital that will support clinical testing of its immuno-oncology drug pipeline.
Insurance group Ping An led a $124m series C round for Apollomics, a US-based developer of oncology combination therapeutics, on Friday through corporate venturing unit Ping An Capital.
The round also featured undisclosed existing and new investors and it increased the company’s funding to about $239m since it was founded in 2016 as CBT Pharmaceuticals.
Spun off by contract research organisation Crown Bioscience International, Apollomics is working on immuno-oncology drugs intended to fight cancer in combination with other therapeutics.
The…
